Neurocrine Biosciences (NBIX) is trading higher as the market continues to digest and revalue the company following its definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, a transaction valuing Soleno at about $2.9 billion. The deal adds VYKAT XR (diazoxide choline), positioned as a rare-disease endocrinology asset targeting hyperphagia in Prader-Willi syndrome, and investors are treating it as an acceleration of Neurocrine’s revenue-diversification strategy.

The acquisition structure is a cash tender offer followed by a merger, and the strategic focus is on turning Soleno’s commercial launch trajectory into a third durable growth pillar alongside INGREZZA and CRENESSITY. Market attention has centered on the commercial potential of VYKAT XR and the near-term visibility created by bringing in a marketed therapy rather than a pre-commercial pipeline bet.

In the week following the announcement, multiple research notes highlighted the acquisition’s potential to expand Neurocrine’s endocrinology and rare-disease footprint and supported higher valuation frameworks, including higher price targets from at least one major sell-side shop. That post-deal target momentum has helped shift sentiment from initial acquirer skepticism toward a more constructive read-through on medium-term earnings power.

Key near-term drivers include tender-offer and closing milestones, any updates on integration expectations and commercial investment levels for VYKAT XR, and incremental clarity on 2026 revenue cadence as Neurocrine layers the acquired product into its portfolio. Investors are also watching upcoming events and the next earnings window for any quantified synergy or expense guidance tied to the transaction.